Arctic Vision Joins Forces with the University of Hong Kong Department of Ophthalmology to Discover and Develop Novel Neuroprotective Therapies for Ocular Disease
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, July 4, 2021 /PRNewswire/ Arctic Vision, a China-based clinical-stage ophthalmology company focuses on developing innovative therapies for pan-ocular diseases, announcing today a new research collaboration with Prof. Christopher Leung, Head and Clinical Professor at the Department of Ophthalmology of the University of Hong Kong (HKU) for the discovery and development of novel neuroprotective therapies for glaucoma.
Glaucoma, an optic neuropathy characterized by progressive loss of retinal ganglion cells (RGCs), is the leading cause of irreversible blindness worldwide.
E-Mail
Eye conditions that do not cause vision impairment but have economic and social consequences represent a serious and growing challenge for public health services worldwide, according to a new paper published by
The Lancet Global Health Commission.
According to research by the Vision Loss Expert Group, led by Professor Rupert Bourne of Anglia Ruskin University (ARU), issues such as glaucoma, sore eyes, conjunctivitis and diabetic retinopathy affected hundreds of millions of people across the world in 2020 without causing moderate or severe vision impairment, and an ageing population means instances of these conditions are growing. In the UK, conditions that do not cause sight loss or blindness account for around 88% of GP consultations related to eye health.
New research article shows millions are living with easily treated ocular conditions Eye conditions that do not cause vision impairment but have economic.
Ageing and vision loss: looking to the future thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.